| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes and TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | ertugliflozin (Steglatro®) |
| Formulation | 5 mg, 15 mg film-coated tablet |
| Reference number | 2146 |
| Indication | As an adjunct to diet and exercise to improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus: as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications; in addition to other medicinal products for the treatment of diabetes |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/06/2018 |
| NICE guidance | TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |